Text Size

Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients (RACHEL)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00931320
First received: June 30, 2009
Last updated: October 23, 2009
Last verified: October 2009
History of Changes
  Purpose

An observational, non-interventional, multi-centre study to provide further information on the ratio of LDL-C to HDL-C improvement after statin treatment in Korean patients group.


Condition
Dyslipidemias

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients

Resource links provided by NLM:

MedlinePlus related topics: Cholesterol Statins
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Evaluate current LDL/HDL ratio in Korean patients (between baseline & after treatment) [ Time Frame: After Treatment : at least 4 weeks before statin taking /Baseline : no limitation. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluate difference of LDL/HDL ratio among different statins & dosages (between baseline & after treatment) [ Time Frame: After Treatment : at least 4 weeks before statin taking / Baseline : no limitation. ] [ Designated as safety issue: No ]

Estimated Enrollment: 3000
Study Start Date: July 2009
Study Completion Date: September 2009
Groups/Cohorts
3000 patients
Who have at least made 1 visit to the outpatient clinic within previous 6 months .

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Who have at least made 1 visit to the outpatient clinic within previous 6 months .

Criteria

Inclusion Criteria:

  • Subjects who are taking lipid-lowering medication after diagnosed as dyslipidaemia
  • Subjects who have at least made 1 visit to the outpatient clinic within previous 6 months
  • Subjects who have records of both LDL-C and HDL-C before & after statin treatment (at least four weeks after statin taking)

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide their examination and lab result of medical chart.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00931320

Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Hyunah Caroline Choi AstraZeneca Korea
  More Information

No publications provided

Responsible Party: Hyunah Caroline, Choi / CV TA Physician, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00931320     History of Changes
Other Study ID Numbers: NIS-CKR-DUM-2009/3
Study First Received: June 30, 2009
Last Updated: October 23, 2009
Health Authority: Korea: Food and Drug Administration

Keywords provided by AstraZeneca:
Ratio improvement
LDL-C
HDL-C
Ratio of Low Density Lipoprotein Cholesterol to High Density Lipoprotein Cholesterol Improvement
High Density Lipoprotein Cholesterol

Additional relevant MeSH terms:
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on May 21, 2013